Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan for bevacizumab-associated hypertension prevention and treatment
ChiCTR1800020093Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olmesartan and bevacizumab in Secondary hypertension (2 arms), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Blood pressure, Ambulatory blood pressure monitoring and 2 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
olmesartanbevacizumab
03
Conditions
Secondary hypertension
Beyond the preview
Go deeper on ChiCTR1800020093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020093.